SincoPharm is a next-generation biopharmaceutical group. We discover, develop and manufacture breakthrough medicines in oncology, immunology, CNS, cardiometabolic and rare diseases — from molecule to market, for 40M+ patients worldwide.
R&D campus, BSL-2/3 labs, fill-finish lines, QC & stability centers.
Founded as Sino-Continental Pharm, SincoPharm (sincopharm.com) grew from a regional generics maker into an innovation-driven biopharma group with 4 R&D centers, 3 GMP mega-sites and 2,400+ people including 480 PhDs. We combine AI drug discovery, continuous manufacturing and uncompromising quality to make advanced therapies affordable.
Medicinal chemistry, immunology, DMPK, bioinformatics and formulation teams in Shanghai, Basel and Boston.
Oral solid dose, sterile injectables, biologics DS/DP, mRNA LNP and lyophilization capacity 2.1B units/year.
Founded, first cephalosporin plant.
EU GMP certification, export to 20 countries.
Biologics R&D center, first mAb IND.
mRNA vaccine platform, WHO PQ.
AI discovery engine + 38 programs in clinic.
Six franchises, one goal: transform standard of care in high-burden and underserved diseases.
OncologyKRAS G12C/D, PARP, ADCs with topo1 payload, PD-1xLAG3 bispecifics. 11 trials in solid tumors & heme malignancies.
Vaccines & ImmunoQuadrivalent influenza, RSV mRNA, HPV-9, IL-17 & TYK2 inhibitors for psoriasis, lupus and IBD.
CNSAlzheimer anti-amyloid, Parkinson LRRK2, treatment-resistant depression, migraine CGRP oral.
Cardio-metabolicGLP-1/GIP dual agonist, oral PCSK9, SGLT2 + finerenone combos, once-weekly insulin.
Rare diseasesAAV for hemophilia A, SMA, DMD exon-skipping, enzyme replacement for lysosomal disorders.
Anti-infectivesNovel beta-lactamase inhibitors, antifungals, long-acting HIV PrEP, TB short-course regimen.
Transparent R&D: every candidate, every phase, every readout. Data cuts updated quarterly.
| Candidate | Indication | Modality | Phase | Progress |
|---|---|---|---|---|
| SCP-101 ADC | HER2+ breast & gastric | Antibody-drug conjugate | Phase III | NDA Q4 2026 |
| SCP-207 KRAS | Pancreatic, CRC | Small molecule G12D | Phase II | ORR 44% interim |
| SCP-312 mRNA-RSV | RSV older adults | mRNA-LNP | Phase III | 28k enrolled |
| SCP-415 GLP-1/GIP | Obesity, T2D | Peptide weekly | Phase IIb | -18.2% weight |
| SCP-520 TYK2i | Psoriasis, lupus | Oral small molecule | Phase III | 2 pivotal trials |
| SCP-630 AAV-HA | Hemophilia A | Gene therapy | Phase I/II | Durable FVIII |
Phase transition success vs 48% industry avg
R&D invested 2020-2026
Patents granted, 410 pending
Peer-reviewed publications
SincoPharm Discovery Cloud screens 4.2B virtual compounds in 48h. Robotic labs run 15,000 assays/week. Organ-on-chip + digital twins cut animal testing by 67%.
End-to-end continuous lines for oral solids reduce variability by 73% and lead time from 45 to 6 days. Real-time PAT release.
HPLC-MS, NMR, NGS, endotoxin, sterility, stability chambers ICH Q1A. 1.2M tests/year, LIMS + blockchain audit trail.
Cold chain 2-8°C validated to -70°C mRNA. 62 countries, 99.4% OTIF, dual sourcing for all critical APIs.
Green chemistry, solvent recycling 91%, solar-powered plants, water-for-injection loop recovery. We publish full ESG + carbon footprint per product.
Scope 1+2 vs 2019 baseline
Renewable electricity in EU sites
Solvents recovered & reused
Doses donated to LMIC programs
Clinical readouts, approvals, partnerships and science explainers. Click any story to read the full article.
For medical information, quality complaints or business development, contact us below. For urgent adverse events, use our 24/7 pharmacovigilance line listed in contacts.
Prescription medicines (Rx), biologics, vaccines, OTC and hospital injectables across oncology, immunology, CNS, cardio-metabolic, anti-infectives and rare diseases.
Yes. All commercial sites are EU GMP and FDA cGMP compliant, with WHO prequalification for vaccines and essential medicines. Audit reports available to partners under CDA.
Send your company profile, licenses, cold-chain capabilities and target portfolio via the contact form. Our alliance team replies within 3 business days.
Yes — from development to commercial: formulation, analytical, sterile fill-finish, lyophilization, biologics DS/DP and packaging with full regulatory support.
On registries and in our newsroom. We commit to publish all Phase II-III results regardless of outcome within 12 months of last patient last visit.
Use the contact form with subject “Pharmacovigilance” or call our 24/7 safety line. Provide product, batch, and contact for follow-up. We handle all reports per GVP.
HQ: SincoPharm Tower, 88 Life Science Ave, Shanghai • Basel • Boston. Licensing, distribution, CDMO, careers.